文献速递前列腺癌男科与性医学

前列腺癌与痴呆的关联:瑞典全国性研究

Associations Between Prostate Cancer and Dementia: A Nationwide Study in Sweden.
PubMed 文献 · Eur Urol Oncol · 2025-04-25

该研究在瑞典全国队列中分析178746例1998-2017年前列腺癌(PC)患者与1787460名年龄匹配对照,发现高危PC仅接受雄激素剥夺治疗(ADT)者阿尔茨海默病(AD)和血管性痴呆(VaD)风险升高,而AD或VaD患者后续PC风险较低,作者建议对ADT治疗的高危PC患者监测痴呆。

要点

  • 高危PC仅接受ADT者AD风险升高(HR 1.37,95%CI 1.19-1.58),VaD风险亦升高(HR 1.51,95%CI 1.29-1.78)。
  • 低或中危PC患者AD风险轻度升高(HR 1.10,95%CI 1.03-1.18),VaD风险无升高(HR 0.90,95%CI 0.83-0.98)。
  • AD或VaD患者后续高危PC风险较低(OR 0.39和0.36),低或中危PC风险亦较低(OR 0.30和0.30)。

核心结论

  • 在高危PC且仅接受ADT治疗的男性中,AD和VaD风险升高,此类患者应监测以及时发现和治疗痴呆。
  • AD或VaD患者后续PC风险较低,可能反映这些亚组筛查减少。

研究设计与样本

  • 全国队列研究纳入1998-2017年瑞典178746例PC患者和1787460名年龄匹配无痴呆对照,采用Cox回归估计至2018年AD和VaD的风险比。
  • 病例对照分析纳入180189例PC患者和1801890名年龄匹配对照,采用Logistic回归估计与既往AD或VaD相关的PC比值比。
  • 亚组分析探讨2005-2017年PC治疗差异,所有分析均校正社会人口学因素和医疗利用。

主要发现

  • 高危PC仅接受ADT者AD风险升高(HR 1.37,95%CI 1.19-1.58),VaD风险升高(HR 1.51,95%CI 1.29-1.78),接受其他治疗者未见升高。
  • 低或中危PC患者AD风险轻度升高(HR 1.10,95%CI 1.03-1.18),VaD风险无升高(HR 0.90,95%CI 0.83-0.98)。
  • AD患者高危PC的OR为0.39(95%CI 0.35-0.45),VaD患者高危PC的OR为0.36(95%CI 0.30-0.42)。
  • AD患者低或中危PC的OR为0.30(95%CI 0.25-0.36),VaD患者低或中危PC的OR为0.30(95%CI 0.24-0.38)。

临床怎么用

  • 作者建议对高危PC且接受ADT治疗的男性监测痴呆,以及时发现和治疗。
  • 作者提出AD或VaD患者后续PC风险较低可能反映筛查减少。

局限性

  • 本研究仅限于瑞典,需要在可行时进行重复验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate cancer (PC) and dementia may commonly co-occur; yet, prior evidence for bidirectional associations is inconsistent. This study aims to determine the associations between PC and dementia in large population-based studies, which may further inform clinical care. METHODS: To assess the dementia risk in men with PC, a national cohort study was conducted in 178 746 men diagnosed with PC in 1998-2017 and 1 787 460 age-matched control men in Sweden without prior dementia. Cox regression was used to estimate hazard ratios (HRs) for Alzheimer's disease (AD) and vascular dementia (VaD) through 2018. Subanalyses explored differences by PC treatment during 2005-2017. To assess the PC risk in men with dementia, case-control analyses were performed in 180 189 men with PC and 1 801 890 age-matched control men. Logistic regression was used to estimate odds ratios (ORs) for PC associated with prior AD or VaD. All analyses were adjusted for sociodemographic factors and health care utilization. RESULTS AND LIMITATIONS: Among men with high-risk PC, those treated with androgen deprivation therapy (ADT) only had a higher risk of AD (HR, 1.37; 95% confidence interval [CI], 1.19-1.58) and VaD (1.51; 1.29-1.78), but not those who received other treatments. Men with low- or intermediate-risk PC had little or no increased risk of AD (HR, 1.10; 95% CI, 1.03-1.18) or VaD (0.90; 0.83-0.98). Men with AD or VaD had lower odds of high-risk PC (OR, 0.39; 95% CI, 0.35-0.45, and 0.36; 0.30-0.42, respectively) and low- or intermediate-risk PC (0.30; 0.25-0.36, and 0.30; 0.24-0.38, respectively). This study was limited to Sweden and will need replication when feasible. CONCLUSIONS: In a large national study, men with high-risk PC treated with ADT had higher risks of AD and VaD. Such men should be monitored for timely detection and treatment of dementia. In contrast, men with AD or VaD had a lower subsequent risk of PC, possibly reflecting reduced screening in these subgroups.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Crump C, Stattin P, Brooks JD, et al. Associations Between Prostate Cancer and Dementia: A Nationwide Study in Sweden. Eur Urol Oncol. 2025. PMID: 40280786. doi:10.1016/j.euo.2025.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。